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Abstract
Introduction The Kathleen Cuningham Foundation Consortium
for Research into Familial Breast Cancer (kConFab) is a
multidisciplinary, collaborative framework for the investigation of
familial breast cancer. Based in Australia, the primary aim of
kConFab is to facilitate high-quality research by amassing a
large and comprehensive resource of epidemiological and
clinical data with biospecimens from individuals at high risk of
breast and/or ovarian cancer, and from their close relatives.
Methods Epidemiological, family history and lifestyle data, as
well as biospecimens, are collected from multiple-case breast
cancer families ascertained through family cancer clinics in
Australia and New Zealand. We used the Tyrer-Cuzick
algorithms to assess the prospective risk of breast cancer in
women in the kConFab cohort who were unaffected with breast
cancer at the time of enrolment in the study.
Results Of kConFab's first 822 families, 518 families had
multiple cases of female breast cancer alone, 239 had cases of
female breast and ovarian cancer, 37 had cases of female and
male breast cancer, and 14 had both ovarian cancer as well as
male and female breast cancer. Data are currently held for
11,422 people and germline DNAs for 7,389. Among the 812
families with at least one germline sample collected, the mean
number of germline DNA samples collected per family is nine. Of
the 747 families that have undergone some form of mutation
screening, 229 (31%) carry a pathogenic or splice-site mutation
in BRCA1 or BRCA2. Germline DNAs and data are stored from
773 proven carriers of BRCA1  or  BRCA1  mutations.
kConFab's fresh tissue bank includes 253 specimens of breast
or ovarian tissue – both normal and malignant – including 126
from carriers of BRCA1 or BRCA2 mutations.
Conclusion These kConFab resources are available to
researchers anywhere in the world, who may apply to kConFab
for biospecimens and data for use in ethically approved, peer-
reviewed projects. A high calculated risk from the Tyrer-Cuzick
algorithms correlated closely with the subsequent occurrence of
breast cancer in BRCA1 and BRCA2 mutation positive families,
but this was less evident in families in which no pathogenic
BRCA1 or BRCA2 mutation has been detected.
BCFR = Breast Cancer Family Registry; BCLC = Breast Cancer Linkage Consortium; FCC = family cancer clinic; kConFab = The Kathleen Cuning-
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Introduction
Ten to fifteen percent of women with breast cancer also have
close relatives affected, and in many multiple-case families
susceptibility to the disease appears to manifest as a domi-
nantly inherited Mendelian trait. The BRCA1 locus on chromo-
some 17 co-segregates with breast cancer and is
characteristic of families in which both early-onset breast and
ovarian cancers occur [1]. A similar proportion of breast can-
cer families, especially those that include one or more cases
of male breast cancer, is linked to a second locus (BRCA2) on
chromosome 13 [2,3].
In the ten years since BRCA1 and BRCA2 were cloned and
sequenced, thousands of pathogenic mutations have been
identified. The original expectation was that carriers of these
mutations would have very high (>80%) lifetime risks of breast
cancer. Such dramatic effects seem to be confined to families
with six or more cases of breast cancer or with a combination
of breast, ovarian and male breast cancers. Population-based
studies show that the average risk to carriers (40% to 65%)
may be somewhat less than in multiple-case families and may
vary between populations [1,4,5]. The prevalence of BRCA1
and BRCA2 mutations (approximately 1:500, but higher in
Ashkenazi Jewish individuals) indicates that they are unlikely to
account for more than 3% to 5% of all breast cancers. How-
ever, mutation carriers from multiple-case families constitute
cohorts in which hypotheses about the role of potential modi-
fying genes and non-genetic risk factors can be tested. Such
analyses need to be complemented by population-based stud-
ies so that estimates of the prevalence, attributable fraction,
and risk of breast cancer can be made for individuals who have
not been selected on the basis of a strong family history [4].
Mutations in BRCA1 and BRCA2 are present in only 35% to
40% of concentrated family clusters of breast/ovarian cancer;
hence it is likely that other 'high-penetrance' breast cancer
susceptibility genes remain to be identified. Multiple-case fam-
ilies also have the potential, given sufficient numbers, to iden-
tify genes, such as CHEK2, that confer lower levels of risk than
BRCA1 and BRCA2, and that are more prevalent in the pop-
ulation [6].
For these and other reasons, a series of discussions within the
Australian cancer genetics and genetic epidemiology commu-
nity in 1995 led to the formation of a national consortium. Its
underlying goal was to foster research into the causes and
impact of familial breast cancer. This would be achieved
through construction of a research resource of genetic, epide-
miological and clinical data, with appropriate biospecimens, to
be available to researchers from anywhere in the world. From
its inception the consortium developed important links with the
network of family cancer clinics (FCCs) around Australia, facil-
itating recruitment into The Kathleen Cuningham Consortium
for Research into Familial Breast Cancer (kConFab) and trans-
fer of research findings to participants and their families. kCon-
Fab received its first funding in 1997 from the Kathleen
Cuningham Foundation [7,8]. We report here on the progress
to date of the consortium, and the characteristics of its first
822 multiple-case families. We demonstrate that the Tyrer-
Cuzick algorithm effectively predicted breast cancer occur-
rence in women unaffected at the time of recruitment if they
were in a family carrying a BRCA1  or  BRCA2  mutation,
though not otherwise. In addition, for these unaffected women,
calculated probabilities of a pathogenic mutation in BRCA1 or
BRCA2 were moderately predictive of such a mutation being
found.
Materials and Methods
kConFab: structure and funding
The aims of kConFab are to collect relevant data and biospec-
imens from families with multiple cases of breast and/or ovar-
ian cancer and to make these widely available, not only to its
members, but to researchers from anywhere in the world for
use in peer-reviewed, ethically approved research projects. To
further enrich the resource, data from these research projects
are returned to kConFab after publication. kConFab's policies
are set by an executive committee, whose membership
includes a consumer representative. Detailed policies and pro-
cedures and reports of progress are available at the kConFab
website [9].
Ascertainment of probands and family members
Since 1997, kConFab has been recruiting multiple individuals
(affected and unaffected by cancer) from families that have
presented to FCCs with evidence of high familial risk of breast
cancer. The eligibility criteria for recruitment of families into
kConFab have evolved over time but are intended to maximize
the number of living potentially high-risk individuals, including
carriers of high-penetrance alleles, whether affected by breast
cancer or not. Families are recruited by research nurses
located in all the largest FCCs in Australia and New Zealand
into five categories described in Table 1.
The families are identified and initially evaluated as part of clin-
ical care in an FCC. The de-identified pedigree is submitted to
kConFab for review and, if judged eligible, the research nurse
approaches a clinic-nominated Family Contact Person. Addi-
tional family members are invited to participate only with the
permission of this person, or another relative subsequently
recruited to kConFab. Participants can be identified from other
sources, for example, by surgeons treating breast cancer
patients from families who appear to fit the 'potentially high
risk' category, although recruitment is again via the kConFab
research nurse.Available online http://breast-cancer-research.com/content/8/1/R12
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After completion of recruitment and data collection, including
verification of the family history of cancer, the pedigree is again
reviewed and the final category recorded. The apparent
strength of family history may have altered as a consequence
of verification of details, and so a proportion of families col-
lected do not fit any category on completion (category 0), most
often because insufficient eligible individuals are alive. These
families are not discarded as later follow-up may provide fur-
ther information that may change their category. Breast, ovar-
ian and other cancers are regarded as 'sporadic' if they affect
individuals in mutation-negative families who are unrelated by
descent to other cases. Most 'sporadic' cancers occur in
spouses who do not themselves appear to have a maternal or
paternal history of breast or ovarian cancer. 'Sporadic' cases
are excluded from the data presented in the tables. The young-
est participating individual in the family affected by breast can-
cer is designated as the index case for the purposes of
mutation testing.
Protocols and procedures
Recruitment and follow-up
Each eligible subject is approached by the research nurse via
the Family Contact Person or another family member and their
informed consent is obtained for participation in kConFab. The
research nurse invites participation by all family members
reported to have been affected by breast or ovarian cancer,
their first-degree relatives, all individuals in ancestral line
between affected individuals and both parents of any of these
eligible individuals. Each subject is then interviewed to estab-
lish their family structure and any reported diagnoses of can-
Table 1
Ascertainment criteria for defined kConFab categories
Category Criteriaa
1 Families in which no predisposing mutation has been identified
Four or more cases of breast or ovarian cancer (on one side of the family) and
Two or more living affecteds with breast or ovarian cancer and
Four or more living first or second degree unaffected female relatives of affected cases
1B Families in which no predisposing mutation has been identified
Two or three cases of breast or ovarian cancer (on one side of the family), if at least one of these cases is 'high risk' (i.e. male breast 
cancer, bilateral breast cancer, breast plus ovarian cancer in the same individual, or breast cancer with onset less than 40 years) 
and
Two or more living affected cases with breast or ovarian cancer and
Four or more living first or second degree unaffected female relatives of affected cases
2 Families in which a BRCA1 or BRCA2 variant has been identified
Two or more carriers, or likely carriers of a pathogenic, splice site or unclassified variantb, for example, two living affecteds, or one 
living affected and at least two living first degree unaffected females of a proven or likely mutation carrier
3 Families with mutations in other breast cancer predisposing genes
Families that carry pathogenic mutations in PTEN, TP53 or ATM, and have two or more living carriers, or potential carriers
4 Potentially high-risk individuals from whom fresh tumor is available, but who do not fit other criteria
Individuals that fit the Australian National Breast Cancer Centre guidelines for high risk of breast cancer (category III) [39], but who 
do not fit other kConFab categories, if they wish to donate fresh breast or ovarian surgical tissue to kConFab
5 Families with two cases of ovarian cancer that do not fit any of the other criteria
Two or three cases of ovarian cancer among first degree relatives, one or more of whom is alive and
Zero or one case of breast cancer and
Four or more living first or second degree unaffected female relatives of affected cases
aAll criteria refer exclusively to individuals over the age of 18. bFamilies with unclassified variants in BRCA1 and BRCA2 were included in category 
2 in order to maximize the opportunities to collect material that might be used in research studies aimed at trying to classify these variants.Breast Cancer Research    Vol 8 No 1    Mann et al.
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cer for themselves or eligible relatives. In 2003, the research
nurses began annual follow-up of families via the Family Con-
tact Person. The main aim is to offer participation to individuals
who have become eligible for kConFab since the family collec-
tion was completed, including newly affected family members,
children who have attained age of majority since the family
ascertainment was completed and first degree relatives of par-
ticipants who have recently become affected with breast or
ovarian cancer. The nurses also approach first-degree rela-
tives of men and women who have learned (through attend-
ance at a FCC) that they carry a BRCA1 or BRCA2 mutation
and notify the kConFab research nurse of this. The approach
to all new participants is always mediated through an already-
consented individual.
Epidemiological risk factor questionnaire
Questionnaires [10-13] covering a broad spectrum of risk fac-
tors are completed by telephone, and appropriate elements
are collected by proxy for deceased eligible individuals.
Biospecimens
Blood collection and processing
A 20 ml sample of anticoagulated blood is collected from all
participants and returned to the central core laboratory by cou-
rier. Participants who are unable to give blood are mailed a
mouthwash kit [14] and 73% of those from whom mouthwash
samples have been requested have returned samples. The
blood processing protocol [15] generates a nucleated cell
product for DNA extraction, Ficoll-hypaque separated lym-
phocytes for Epstein Barr virus transformation, non-lym-
phocytic leukocytes for further DNA or RNA extraction,
Guthrie cards of blood spots, and plasma aliquots. DNA is
extracted as required (QIAamp DNA blood kit, Qiagen GmbH,
Hilden, Germany). Lymphoblastoid cell lines are established
by Epstein Barr virus transformation as required for research
projects or to replace DNA stocks as they are depleted.
Collection of fresh normal and tumor specimens
Subjects are encouraged to report if and when they are to
have breast or ovarian surgery for prophylaxis or cancer treat-
ment. Chilled specimens are grossly dissected into 3 mm sec-
tions by the clinical pathologist, placed in a histocassette and
snap frozen in liquid nitrogen and transferred on dry ice by
courier to the kConFab tissue bank. In the case of prophylactic
mastectomy, portions containing connective tissue are sepa-
rated from fat as much as possible and marked as such by the
pathologist. In remote locations, or where dry ice is not readily
obtainable, specimens are collected and transported in
RNAlater (Ambion, Austin, TX, USA). A pro forma question-
naire about menstrual status is completed by women who
donate tissues.
All material received in the bank undergoes standardized eval-
uation and processing, including a report on transfer condi-
tions and state of the shipment on arrival, an assessment of the
nature of the specimen and a record of number and size of
pieces. After the final histopathology report is obtained, the
frozen sections of the sample are examined after haematoxylin
and eosin staining (5 µm sections) and five thick (10 µm) sec-
tions are then stored in a cryovial in liquid nitrogen. A further
'bookend' thin section is taken for haematoxylin and eosin
staining to document the tumor content of the next level of the
specimen.
Cancer verification
kConFab uses several methods to verify all reports of cancer
in the family: through medical records or state-based cancer
registries and by systematic searches by the Database Man-
ager of Australian cancer registry records of all eligible con-
sented living participants and deceased family members. The
state-based cancer registries have been collecting data since
1982 (and some back to 1970), but most have only recorded
ductal carcinoma in situ since 1982. The final level of verifica-
tion that is reached is noted and, where possible, a copy of the
final pathology report is obtained from which the location of
archival, diagnostic tumor specimens is recorded so that par-
affin blocks and slides can be requested as necessary.
Genotyping
Mutation detection
Testing for BRCA1  and  BRCA2  mutations has been per-
formed in 747/822 (91%) of families. In most cases the enroll-
ing FCC will already have undertaken diagnostic testing using
a clinical DNA sample from an affected family member accord-
ing to their local protocols, which were estimated to be about
80% sensitive prior to 2001. Since 2001 most diagnostic lab-
oratories in Australia have adopted denaturing high perform-
ance liquid chromatography as the method of choice for
BRCA1 and BRCA2 mutation analysis, with estimated 96%
sensitivity for exonic and splice-junction variants [16]. Testing
of index cases in kConFab families has also been carried out
by complete sequencing through Myriad Genetics (Salt Lake
City, UT, USA) with the support of a grant from the National
Cancer Institute to the Australian Breast Cancer Family Regis-
try [11]. Families prioritized for complete sequence analysis
are those with no previous clinical mutation testing because,
for example, no affected member of the family wanted a clinical
mutation test result, or because the family fulfill the entry
requirements of a genome-wide linkage study being under-
taken in collaboration with the Breast Cancer Linkage Consor-
tium [1]. In addition, all individuals who have provided a fresh
frozen breast tumor (cancer) specimen are tested by full
sequencing unless they are already known to be positive for a
family-specific mutation in BRCA1 or BRCA2. Analysis for
genomic deletions and rearrangements detectable by multi-
plex ligation-dependent probe amplification [17] is currently
underway.
kConFab classifies all BRCA1 and BRCA2 variants reported
by diagnostic or research laboratories into categories: patho-Available online http://breast-cancer-research.com/content/8/1/R12
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genic, splice-site variant, variant of unknown significance and
polymorphism. The criteria for classification are posted on
kConFab's website [18].
Once the family mutation has been identified, all pathogenic
(including splice site) variants of BRCA1 and BRCA2 are gen-
otyped by kConFab in all available family members' DNA.
Access to the unique family number linking a variant to a par-
ticular family is password protected and is only available to
investigators carrying out kConFab-related research. De-iden-
tified, individual mutation results are available only to research-
ers, and not to the originating research nurse(s) or health
professionals in the FCC(s) that the family attends.
All index cases of non-BRCA1/2 families are genotyped by
kConFab for the breast-cancer related mutation in ATM,
7271T>G [19], and a small number of families with features of
Li Fraumeni syndrome have been tested for mutations in p53
by the diagnostic laboratories.
Haplotyping at BRCA1 and BRCA2 loci
Mutation-negative families with female breast cancer, in which
sufficient quantities of DNA are available from at least three
affected individuals, have been analyzed for haplotype sharing
at short tandem repeat polymorphism (STRP) markers flanking
and internal to BRCA1 (D17S800, D17S855, D17S951,
D17S1322) and BRCA2 (D13S260, D13S1700, D13S171,
D13S267) in order to select families suitable for genetic link-
age analysis for novel susceptibility loci.
Informatics
The Central Register, located at the Peter MacCallum Cancer
Centre, until recently received data from peripheral versions of
a Family Based Information database, developed by the Can-
cer Council of Victoria, by periodic uploads from the recruiting
clinic-based research nurses. During 2005, we implemented a
TCP-IP based application to permit live access to the central
data server from multiple remote locations, based on a Prog-
eny Anywhere (Progeny Software LLC, Grand Rapids, MI,
USA) XML-compliant front end. Data in the Central Register
can be accessed only by procedures that are ethically
approved and in accord with national guidelines on privacy of
genetic information [20]. Information is stored both by individ-
ual and by family. Individual data include personal and demo-
graphic information, biological relationships, cancer
diagnoses, cancer treatments, epidemiological information,
biological specimens, genotyping and mutation test results, as
well as a variety of process and management outcomes.
Periodic checks are run to determine if individuals have been
registered through more than one family and, if confirmed and
appropriate to the family structure, the families are merged
within the Central Register. In this way, and through other con-
sent-approved communication between family cancer clinics,
43 families with individuals in common have been merged into
21, ensuring data and specimens for each individual are only
accessed once, and that the combined characteristics of the
entire family structure can be analyzed by researchers.
Quality control
Identity and DNA quality are checked on a randomly selected
10% of the DNAs extracted from leukocyte pellets by PCR
amplification of five unlinked STRP markers. These genotypes
are compared with those from DNA from the matching Guthrie
spot. To date, all DNAs tested in this way have yielded PCR
product, and none have shown mismatches with the Guthrie
spot DNA.
After its initial submission, and whenever genotyping has been
extended within a family as a result of a newly detected muta-
tion, the pedigree is reviewed by a geneticist for internal con-
sistency of the family structure, dates of birth, cancer
diagnosis and death, and for Mendelian inheritance of known
genotypes. Using DNA isolated from a Guthrie spot, we repeat
testing for the family-specific mutation in any individuals with
apparently anomalous results; for example, unaffected but
mutation-positive individuals with no confirmed carrier or
affected offspring, who were linked to the closest confirmed
carrier by two or more unaffected individuals of unknown gen-
otype. To date, these and other types of quality control have
not revealed any genotyping errors.
Pathology review
A standardized review of original or duplicate diagnostic slides
from all index cases in families in which no mutation in
BRCA1/2 had been identified was begun in 2004 with the aim
of identifying those cases with a phenotype suggestive of a
BRCA1 mutation in order to direct additional mutation testing,
and to determine if there are distinct pathological phenotypes
by which these families could be stratified. The review, aided
by a reference document, involves recording tumor size, lymph
node and hormone receptor status from original pathology
reports and examining slides to evaluate tumor type and grade
as well as features of particular significance to familial breast
cancer such as lymphocytic infiltrate and the extent of a push-
ing tumor margin [21].
Communication with subjects
kConFab maintains contact with participants, collaborating
doctors, pathology laboratories and funding bodies through a
newsletter, published once or twice yearly, describing kCon-
Fab's progress and providing other general information about
familial breast and ovarian cancer. In addition, as the results of
genetic tests performed by kConFab become available, partic-
ipants are contacted if they have indicated a wish to be
informed 'if there is a test result (obtained by kConFab) that
may have implications for me or my family'. This process is acti-
vated when a mutation of pathogenic significance has been
identified in a member of the family, and all available samples
from the family have been genotyped. kConFab's letter to par-Breast Cancer Research    Vol 8 No 1    Mann et al.
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Table 2
Family characteristics: cancer type, density and BRCA1/2 mutation status
Female breast 
cancer only
Female breast 
and ovarian 
cancer
Ovarian 
cancer only
Male breast 
cancer only
Female and 
male breast 
cancer
Female breast, 
male breast 
and ovarian 
cancer
No breast or 
ovarian 
cancera
Total number 
of UFNsb
Total number of 
UFNs
518 239 4 3 37 14 7 822c
Number of affecteds per family
<3 100 14 3 3 4 0 7 131
3–5 330 143 1 0 21 5 0 500
>5 88 82 0 0 12 9 0 191
Median age at 
diagnosis (range)
49 (20–91) 48 (22–89) 51 (36–57) 63 (47–68) 54 (30–87) 53 (31–86) - 49 (20–91)
Median number of 
individuals with 
breast or ovarian 
cancer (range)
4 (1–14) 5 (1–19) 1 (1–3) 2 (1–2) 4 (2–12) 6.5 (3–17) - 4 (0–19)
Number of families by BRCA1/BRCA2 mutation statusd
BRCA1 pathogenic 
or splice site 
mutation
42 71 2 0 1 2 4 122
BRCA1 unclassified 
variant only
1 9 700000 2 6
BRCA2 pathogenic 
or splice site 
mutation
60 32 1 1 7 6 0 107
BRCA2 unclassified 
variant only
21 12 0 0 3 0 0 36
BRCA1 or BRCA2 
variant not yet 
classified
5500000 6
No BRCA1 or 
BRCA2 mutation: 
complete testinge
84 36 0 0 12 4 0 136
No BRCA1 or 
BRCA2 mutation: 
incomplete testing
231 69 1 1 10 2 0 314
Not yet tested for 
BRCA1 or BRCA2
56 11 0 1 4 0 3 75
The table shows the number of tumors reported and verified in all available generations on the genetically informative side of families. aSeven 
families had no cases of breast or ovarian cancer at the time the database was surveyed. Since then cancer diagnoses have been downloaded to 
the Central Registry for four families that had been downloaded prematurely, one family has been merged with another that contains cases of 
cancer, and two more families are category 4, with a member who wished to give fresh tissue to kConFab, but no additional information is available 
on their affected relatives. bUFN, unique family number. cMerged families are counted by their individuals components, not as a merged pedigree. 
dSome families have a pathogenic or splice site mutation as well as an unclassified variant, and some families have two unclassified variants. eAt 
least one person tested by high-sensitivity methods for BRCA1 and BRCA2 mutations.
ticipants does not provide an individual result, but rather says
that genetic information 'relevant to the family' is now available.
The letter goes on to explain how and where to seek further
advice and clinical testing in an accredited laboratory via a
FCC. kConFab notifies the relevant diagnostic laboratory of
the nature of the family mutation, but does not supply individual
research results to the laboratory.
Ethics
kConFab maintains human ethics approval at all participating
institutions through which subjects are recruited. All research
projects making use of data and/or materials collected by
kConFab are required to have independent ethical approval
from their host institutions. All participants give informed con-
sent and understand that as a result of participation, personal
details will be recorded and stored in a coded format on a
database. They consent to samples of genetic material, bloodAvailable online http://breast-cancer-research.com/content/8/1/R12
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cells and tissue (if applicable), being stored in a central loca-
tion and to de-identified information and samples being made
available for scientifically and ethically approved research
projects.
Access to data and biospecimens
Applicants wishing to use data and/or biospecimens first sub-
mit a brief expression of interest, which is circulated to the
entire kConFab membership with a five-day opportunity given
to highlight major issues, especially duplication of, or comple-
mentarity to, existing projects. A full application is then submit-
ted and checked against criteria that include evidence of
external peer review, sufficient resources to conduct the
project, and ethics approval. Given that these conditions are
met, approval is given for up to three years, during which
annual progress reports are a requirement, and after which the
project can be renewed if not complete. To further enrich the
kConFab resource, the researchers are required to supply
their research data to kConFab after publication, and/or 12
months after completion of their project [22].
Analysis of breast cancer risk
The Tyrer-Cuzick algorithm [23] was developed to model
breast cancer risk in unaffected women by taking into account:
their probability of carrying genetic risk factors, namely a rare,
high penetrance mutation in BRCA1 or BRCA2 and a notional
common, low-penetrance dominant susceptibility allele that
stood for all other genetic risk factors; and a range of other
individual clinical and epidemiological factors known to influ-
ence risk, such as menarche and parity. The genetic risk com-
ponent of the calculations derives from a Bayesian
segregation analysis that takes into account known BRCA1/2
genotyping data and family history of breast cancer in first- and
second-degree relatives.
A batch program kindly provided by Dr Jack Cuzick [23] was
used to estimate the risk of breast cancer in the next decade
for all women in the kConFab cohort who had not previously
had breast cancer at time of recruitment. The reference date
for the subject was the date of epidemiological risk factor
interview, but the family data used (family structure and cancer
diagnoses in relatives) were those that had been reported in
the family by the date of analysis, not only those reported at the
time of interview. Two calculations were performed, one in
which all reports of previous family breast cancer diagnoses
were taken into account, and one including only the verified
reports. The program was also used to calculate the probabil-
ity of testing positive for a BRCA1 or BRCA2 mutation. It is
recognized that the circumstances of genetic testing of indi-
viduals in the kConFab cohort were often far from those for
which this aspect of the algorithm was designed, namely the
initial screening of an index case in a previously untested fam-
ily. Receiver operating characteristic (ROC) analysis of the
sensitivity and specificity of these estimates was performed
using STATA 7.0 (College Station, TX, USA).
Results and Discussion
Family characteristics and biospecimen collection
The majority (518; 63%) of the 822 families in this cohort have
cases of female breast cancer in successive generations, but
no cases of ovarian or male breast cancer (Table 2). Families
having both female breast and ovarian cancer account for
most of the remaining families (239; 29%). Male breast can-
cers were reported in only 54 families (7%). The median
number of breast or ovarian cancers per family was 4 (range 0
to 19), with 691 (84%) families having at least three and 191
(23%) having at least five.
Pathogenic (including splice site) mutations in BRCA1  or
BRCA2 have been detected in 229 families. There are 62 fam-
ilies with only unclassified variants in BRCA1 or BRCA2, while
six families have variants that have not yet been categorized. In
the 525 families without a BRCA1 or BRCA2 pathogenic,
splice-site mutation or unclassified variant, genetic testing has
been completed on at least one member of the family for 136
families, with 314 having had partial testing, and 75 no testing.
Table 3
Median age of onset of first diagnosis of breast or ovarian cancer in BRCA1/2 carriers and non-carriers
BRCA1 carrier of a 
pathogenic or splice 
site mutation
BRCA2 carrier of a 
pathogenic or splice 
site mutation
BRCA1 carrier of an 
unclassified variant
BRCA2 carrier of an 
unclassified variant
No identified 
mutations
Females with breast 
cancer (range)
40 (23–70) 42 (24–79) 44 (22–88) 43 (29–79) 50 (15–90)
Females with ovarian 
cancer (range)
50 (33–80) 56 (45–77) none 80 (80-80) 55.5 (27–79)
Females with breast 
and ovarian cancer 
(range)
50 (26–85) 60 (41–73) 62.5 (55–75) none 53 (30–75)
Males with breast 
cancer (range)
none 68.5 (46–86) none none 62 (31–75)Breast Cancer Research    Vol 8 No 1    Mann et al.
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The median age at diagnosis of female breast cancer, male
breast cancer and ovarian cancer in BRCA1 and BRCA2 car-
riers or pathogenic or unclassified variants and those without
identified variants are given in Table 3. As expected, the
median age at diagnosis of the first female breast cancer was
lower in BRCA1 and BRCA2 carriers than in those women
without mutations.
Although testing is incomplete, only two families (Table 1, cat-
egory 3) have identifiable mutations in genes other than
BRCA1 or BRCA2 that are likely to have conferred a high risk
of breast cancer. One family has a mutation in TP53 and
another has a 7271T>G mutation in ATM  [19] (Table 4).
Twenty-five potentially high-risk families were enrolled into
kConFab (Table 1) because a family member wanted to give
fresh surgical tissue, but the family did not fit other kConFab
ascertainment criteria.
Germline DNA samples have been collected from 7,389 indi-
viduals (Table 4). Epidemiological questionnaires have been
collected from 7,039 individuals, with more limited data con-
cerning a further 4,383 deceased relatives collected by proxy
(Table 4). Participation has been greater by female than male
family members, with females accounting for 65% of the
biospecimens and 64% of the questionnaires provided.
The mean number of germline DNA samples collected per
family is nine (median of eight; Table 5). From 122 families,
germline DNA samples were collected from three or more
affected individuals (Table 5). Lymphoblastoid cell lines are
currently available for 462 subjects, and can be made from any
consented individuals from whom at least 10 ml blood was
collected (92% of all blood samples).
Verification was obtained for 1,808/3,135 (57.7%) reported
female breast cancers, 159/329 (48.3%) ovarian cancers, 27/
60 (45.0%) male breast cancers and 690/2,580 (26.7%)
other cancers. Family review identified 37 'sporadic' cases in
mutation-negative families, from 7 of whom we have germline
DNA. Fresh tissue has been frozen (or stored in RNALater for
11%) for 253 specimens (Table 6). These include 45 breast
tumors, 6 ovarian tumors, and 75 normal breast and 73 normal
ovary specimens from prophylactic surgery.
BRCA1 and BRCA2 mutations
BRCA1 and BRCA2 variants identified in kConFab families
are listed on the website [18]. Pathogenic (including splice-
Table 4
Availability of germline DNA specimens and epidemiological data
Family ascertainment categorya Review pending Total
11 B2 3 4 5 0
Number of families 292 113 217 2 25 8 140 25 822
Number of samples
From females 
(affected)
2,118 (735) 577 (215) 1,239 (385) 19 (6) 45 (21) 22 (12) 621 (179) 124 (44) 4,765 (1597)
From males 
(affected)
1,179 (7) 274 (6) 759 (5) 5 (0) 28 (0) 14 (0) 322 (4) 43 (0) 2,624 (22)
Totalb 3,297 851 1,998 24 73 36 943 167 7,389
Number of 
epidemiological 
questionnaires
Females (affected) 2,033 (703) 526 (193) 1,226 (386) 18 (13) 31 (13) 18 (9) 585 (163) 100 (37) 4,537 (1510)
Males (affected) 1,122 (5) 262 (6) 745 (5) 5 (0) 18 (0) 11 (0) 303 (3) 36 (0) 2,502 (19)
Totalc 3,155 788 1971 23 49 29 888 136 7,039d
Number of proxy 
epidemiological 
questionnaires
Female (affected) 889(460) 226 (81) 694 (410) 48 (1) 25 (13) 7 (4) 382 (160) 53 (31) 2,284 (1160)
Male (affected) 862 (7) 206 (3) 608 (9) 11 (0) 18 (0) 5 (0) 336 (1) 53 (1) 2,099 (21)
Totale 1,751 432 1,302 19 43 12 718 106 4,383
aFinal category (Table 1) after review. bGermline DNA mainly from blood samples but includes 22 obtained from mouthwash specimens. 
cEpidemiological questionnaires. dThe lower number of epidemiological questionnaires than biospecimens reflects a time-lag in collecting them 
from the research nurses, and scanning them. eEpidemiological questionnaire data obtained for deceased individuals by proxy.Available online http://breast-cancer-research.com/content/8/1/R12
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site) BRCA1 mutations were detected in 122 of the families
and variants of uncertain significance (unclassified variants) in
26 (Table 2). Pathogenic (including splice-site) BRCA2 muta-
tions were detected in 107 families and unclassified variants
in 36. The frequency of pathogenic and splice-site mutations
in BRCA1 or BRCA2 in families that had had at least some
mutation screening was 31% (229/747), while unclassified
variants were found in a further 8% (62/747). Even after muta-
tion screening of selected families by full sequencing, only
51% (229/453) families were found to carry BRCA1  or
BRCA2 mutations. However, this figure is likely to increase as
testing (including screening for large genomic rearrange-
ments) is completed across the entire cohort. Biospecimens
and data are available from 773 proven carriers of BRCA1 or
BRCA2 pathogenic and splice site mutations (including 558
females, of whom 342 are affected by breast or ovarian can-
cer), and data from a further 127 obligate carriers (93 female,
including 81 affected) (Table 7). There were 15 cases from
mutation-positive families with female breast or ovarian cancer
who did not carry the family mutation. BRCA1 and BRCA2
mutation status is known for approximately half the donors of
fresh tissue biospecimens (Table 6). For example, there are 16
breast tumors, 34 prophylactic mastectomy specimens and
53 prophylactic oophorectomy specimens from proven
BRCA1 and BRCA2 carriers in the tissue bank.
Because the initial screening for BRCA1 and BRCA2 muta-
tions was performed by local diagnostic laboratories using
protocols of varying sensitivity, a systematic attempt is under-
way to identify additional mutations using full sequencing of
BRCA1 and BRCA2, which has been performed in 168 cases
(from 163 families). Therefore, 178 families are regarded as
'non-BRCA1/2' by sensitive testing methods, although 42/
178 have unclassified variants in BRCA1 or BRCA2.
To date, 20 families carry mutations that are believed to have
resulted from Alu  recombination events resulting in large
genomic deletions and rearrangements in BRCA1. The com-
mon and well-characterized mutation BRCA1 exon 13 dupli-
cation accounts for 8 of these families and 12 families carry
variants of either single or multiple exon deletions and duplica-
tions. The five families whose genomic rearrangements have
not yet been fully characterized are not included as mutation-
positive in the tables.
Genotyping has been used to select families suitable for
genetic linkage analysis for non-BRCA1, non-BRCA2  high
penetrance susceptibility loci, namely those in which all
affected individuals do not share a haplotype at BRCA1 or
BRCA2 (Table 8). Haplotyping has also been useful in redi-
recting mutation analysis, for example if the majority of affected
individuals in the family shared a BRCA1 or BRCA2 haplotype
but the screened individual(s) did not, and to prioritize families
for more intensive mutation analysis such as full sequencing or
genomic rearrangement analysis. Where germline DNA sam-
ples were available from at least three affected individuals,
haplotyping at STRP markers flanking BRCA1 and BRCA2
was carried out in BRCA1, BRCA2 mutation-negative fami-
lies.
Table 5
Availability of germline DNA specimens by cancer family type
Type of cancer 
family
Mean number of 
blood samples per 
family (range)
Samples from affecteds/family (number of families)
0< 22> 2 A l l  f a m i l i e s
Female breast 
cancer only
8.6 (1–36) 98 186 166 68 518
Female breast and 
ovarian cancer
10.3 (1–37) 42 79 78 40 239
Ovarian cancer 
only
4.8 (2–7) 2 1 1 0 4
Male breast 
cancer only
4.3 (2–8) 0 3 0 0 3
Female and male 
breast cancer
8.1 (2–18) 9 12 8 8 37
Female breast, 
male breast and 
ovarian cancer
13.8 (2–30) 1 4 3 6 14
All families with 
breast or ovarian 
cancer
9.1 (1–37) 152 285 256 122 815Breast Cancer Research    Vol 8 No 1    Mann et al.
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Research projects supported
Since 1998, 45/48 research project applications have been
given approval to use kConFab biospecimens and data, one
third of these in the last two years. The average time from
receipt of an application to approval of the project has been
four months, which usually includes some clarification of the
protocol with the applicant. Three projects did not go ahead
because of lack of funding or the unwillingness of the host
institution to sign a materials transfer agreement. Active
research projects are listed on the kConFab website [24]. The
investigators involved come from multiple institutions in Aus-
tralia, one in the United States, one in the United Kingdom and
one in France. To date, these projects have resulted in 29 pri-
mary research publications [25], ranging from reports on the
cumulative risk of breast cancer in families with BRCA1 and
BRCA2  mutations to studies of psychological morbidity in
these families [8,19,26-37].
Quantification of breast cancer risk
The risk of breast cancer in the ten years after recruitment was
calculated for all 4,815 unaffected female kConFab subjects
in which epidemiological interview data, collected directly or
by proxy, were available. This risk was expressed as either the
absolute risk or as a ratio of population risk for that individual
(relative risk).
In the cohort as a whole, the distribution of relative risk indi-
cated that our ascertainment scheme and procedures had
been reasonably efficient. The median relative risk was 2.47,
with 91% of subjects having a risk higher than that of a woman
in the population of the same age and 859 (18%) having a
more than 5-fold elevation.
The graphs in Fig. 1 show the relationship between the prob-
ability of having developed breast cancer for the first time
since interview and the cumulative risk over the period of fol-
low-up as calculated using the Tyrer-Cuzick model. Over this
time (median 4.2 years) there were 107 cases of breast can-
cer confirmed by medical records, 2.9% of the 3,657 women
alive at the time of initial data collection. This was very close to
the 110 cases expected. Women in the highest risk quintile
(absolute risk > 0.14, relative risk > 10.1) accounted for 49 of
those cancers (46%, data not shown). Overall, 55 cancers
(51%) occurred in women in the highest quintile of cumulative
risk, in which length of follow-up was taken into account (Fig.
1a). In families with a pathogenic BRCA1 or BRCA2 mutation,
women in the highest quintile of cumulative risk experienced
almost all, 92% (36/39), of the cancers (Fig. 1b). In contrast,
families without a BRCA1  or  BRCA2  mutation showed a
weaker, but more linear relationship between calculated
cumulative risk and the probability of subsequent breast can-
cer (Fig. 1c). Interestingly, there was no gain in predictive
power when the cancer diagnoses in family members, used in
the risk calculation, were restricted to those verified from med-
ical records rather than using all reports (data not shown). For
example, women in the highest quintile of cumulative risk expe-
rienced 55 of the 107 breast cancers when the verified data
were used, exactly as above. The data for BRCA1  and
BRCA2 mutation positive families, using verified data only,
were also essentially identical to those in Fig. 1b.
High risks calculated by the Tyrer-Cuzick algorithm therefore
correlated well with future incidence of breast cancer, but this
effect was much stronger in BRCA1/2 mutation positive fam-
ilies than in BRCA1/2 mutation negative families.
Table 6
Mutation status of individuals from whom fresh frozen normal and malignant ovarian and breast specimens have been obtained
Type of surgery/tissue BRCA1 mutation 
positive
BRCA2 mutation 
positive
BRCA1/2 mutation 
negativea
Unknown Total
Breast
P r o p h y l a c t i c / t u m o r 00101
Prophylactic/
normal
18 16 2 39 75
Cancer/tumor 9 7 15 13 44
Cancer/normal 6 5 11 17 39
Ovary
P r o p h y l a c t i c / t u m o r 00011
Prophylactic/
normal
27 26 0 20 73
C a n c e r / t u m o r 40015
C a n c e r / n o r m a l 6207 1 5
aNegative following full sequencing, denaturing high performance liquid chromatography or chemical cleavage.Available online http://breast-cancer-research.com/content/8/1/R12
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Prediction of BRCA1 and BRCA2 mutation status
The Tyrer-Cuzick batch program was also used to calculate
the posterior probabilities that an unaffected woman was a
carrier of a BRCA1  or BRCA2  mutation. These estimates
were compared with the actual prevalence of BRCA1 and
BRCA2 mutations in these individuals. No data on the pres-
ence of these mutations were used in the generation of the
estimates. This aspect of the algorithm was developed for use
in the context of an unaffected woman presenting from a family
in which no mutation screening had been done. Its application
to all unaffected women in the kConFab cohort is somewhat
artificial because in many cases they were recruited into kCon-
Fab after a family mutation had already been found. Nonethe-
less, the proportion of women testing positive for a BRCA1
mutation is seen to correlate well with the estimated probabil-
ity of BRCA1 mutation (Fig. 2a). The quintile with the highest
probability showed more than six times the prevalence of
BRCA1 mutations in the lowest quintile; the area under the
ROC curve was 0.67. There was also positive correlation
between the BRCA1 estimate and the observed prevalence of
BRCA2 mutations (Fig. 2a). Interestingly, the estimated prob-
ability of BRCA2 mutation was somewhat less effective than
the estimated probability of BRCA1 mutation in predicting the
presence of a BRCA2 mutation (Fig. 2b): the area under the
ROC curve was 0.61.
Conclusion
Knowledge of the underlying determinants of breast and ovar-
ian cancer risk is still very incomplete. kConFab has therefore
focused on recruitment and comprehensive characterization
of a cohort of women at significantly higher than average risk
of breast and/or ovarian cancer, together with large numbers
of their relatives. This approach has already been productive in
yielding many carriers of known predisposing mutations, and it
is expected that these numbers will increase as BRCA1 and
BRCA2 testing is completed, and as new predisposing genes
are discovered. The cohort of kConFab families is a fertile
resource for research and already supports a wide range of
projects. Data collection is complete for 518 families with
female breast cancer only, 239 with female breast and ovarian
cancer, and 54 with male breast cancer alone, and/or with
female breast and ovarian cancer. Data are available for
11,422 consented participants, including 900 carriers of path-
ogenic or splice site BRCA1 or BRCA2 mutations, and germ-
line DNA biospecimens for 7,389, including 773 carriers.
Fresh frozen tumor and normal specimens are available for
253 participants.
Ascertainment to kConFab is not population based, but is
dependent on clinical identification of individuals at high risk of
breast and ovarian cancer. Data and analyses derived from
cohorts of this type are shaped by the selection criteria used
Table 7
BRCA1 and BRCA2 mutation carriers
Mutation statusa Number of 
mutations
Number of families Number of female carriers (obligateb) Number of male carriers (obligateb)
All Affected All Affected
BRCA1
Pathogenic 62 118 282 (56) 175 (51) 115 (18) 0 (0)
Splice site 4 4 13 (3) 10 (2) 7 (0) 0 (0)
Unclassified 
variant
22 27 81 (4) 46 (3) 30 (2) 0 (0)
Total 88 149 376 (63) 231 (56) 152 (20) 0 (0)
BRCA2
Pathogenic 58 98 237 (32) 140 (26) 85 (11) 5 (1)
Splice site 5 9 26 (2) 17 (2) 8 (5) 0 (1)
Unclassified 
variant
31 43 99 (2) 57 (2) 38 (3) 1 (0)
Total 94 150 362 (36) 214 (30) 131 (19) 6 (2)
Total BRCA1 and 
BRCA2
182 299 738 (99) 445 (86) 283 (39) 6 (2)
aAfter exclusion of common polymorphisms, mutations and variants were classified according to the kConFab classification scheme [18]; some 
families have pathogenic or splice site mutations, as well as an unclassified variant, some families have two unclassified variants, and some 
unclassified variants occur in more than one family. bObligate carriers are classified as 'definite' obligate carriers if one of their offspring and a 
maternal or paternal relative are both proven carriers, and 'probable' obligate carriers if they are a parent of one or more proven carriers but the 
other declared biological parent(s) is a proven non-carrier. Numbers of definite and probable obligate carriers (based on pedigree analysis) are in 
addition to tested carriers.Breast Cancer Research    Vol 8 No 1    Mann et al.
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to refer families to FCCs, the specific kConFab ascertainment
criteria, and by the dynamics of family participation in research.
Such clinic-based studies cannot replace population-based
approaches but are complementary to them, and this project
has already provided several examples of productive collabo-
ration [19]. However, we are only recruiting a small proportion
of high-risk breast cancer families in Australia and New Zea-
land, and recruitment is not yet reaching a plateau. The
number (1,159) of BRCA1/2 mutation carriers for whom data
is currently held is approximately 5% of the number predicted
from the plausible population frequency of these alleles and
the current population size of 22 million. By the time recruit-
ment of the kConFab cohort is complete, we estimate that we
will have enrolled approximately 10% of multiple case families
from Australia and New Zealand. Further analyses will be
needed to test how representative the cohort is of the diverse
populations of our two countries.
The establishment of an organization such as kConFab cannot
be achieved without some difficulties. For example, large scale
centralized pathology review of breast and other cancers
occurring in kConFab participants is beyond the scope of cur-
rent core activities. As a consequence, systematic review has
focused on index cases of non-BRCA1/2 families since these
data are likely to be of value to research projects. Additional
pathology data are contributed to kConFab by investigators
who undertake review in the context of specific research
projects.
Follow-up contact with the families has also proved challeng-
ing. For example, recontacting subjects for projects that
include the study of known mutation carriers requires very
careful attention to ensure that the presence or absence of a
family mutation is not revealed to individuals who do not know,
or want to know, their mutation status. Projects that involve
approaching both mutation-positive and mutation-negative
members of families, and can be done blind to the mutation
status, are easiest to accommodate within kConFab.
One of the most difficult issues has been to ensure that the
participants understand the differences between 'research'
and 'clinical' mutation testing. Anecdotal evidence suggests
that many participants still confuse the issues, and expect
kConFab to give them individual mutation results. Most of the
people enrolled in kConFab are not clients of FCCs, but rela-
tives of people who are. Consequently, kConFab's notification
letters do not tell individuals about their own carrier status, but
state that a family specific mutation has been discovered and
that if the individual wishes to know his/her carrier status, he/
she should contact an FCC. A second blood sample can then
be taken and tested in an accredited laboratory for the pres-
ence or absence of the family specific mutation. The result of
this test is then given to the individual, after counseling.
Even though kConFab's ascertainment strategy is targeted to
individuals with a potentially high risk of breast or ovarian can-
cer and their relatives, the family pedigrees contain many fam-
ily members who are not necessarily at high risk, for example,
spouses with no blood relationship to the cases of breast or
ovarian cancer in the pedigree. Studies based on the second-
ary recruitment of potentially high-risk individuals within the
kConFab cohort, for example, examining the determinants of
clinical outcome or of psychological adjustment to high risk of
cancer, have had to take additional steps to remove such indi-
viduals from their ascertainment, including implementing a sys-
tem of risk stratification within the cohort.
kConFab can be compared to the European-based Breast
Cancer Linkage Consortium (BCLC), which focuses on fami-
lies ascertained through family cancer clinics, and the NCI-
funded Breast Cancer Family Registry (BCFR) that includes
both clinic-based and population-based sites. There are
enough similarities between these cohorts to allow collabora-
Table 8
Haplotype sharing in BRCA1/2 mutation negativea families
Family type BRCA1 haplotype 
sharedb
BRCA2 haplotype 
sharedb
BRCA1 and BRCA2 
haplotype shared
Neither BRCA1 nor 
BRCA2 shared
Total
Female breast cancer only 13 10 10 46 79
Female breast and ovarian cancer 11 3 0 15 29
Ovarian cancer only 0 0 0 0 0
Female and male breast cancer 1 2 1 3 7
Female and male breast cancer and 
ovarian cancer
00 0 4 4
Male breast cancer only 0 0 0 0 0
Total 25 15 11 68 119
aIndex cases screened by high-sensitivity methods. bAll cases from families on whom at least three blood samples were available from cases 
affected by breast or ovarian cancer share alleles at all markers tested.Available online http://breast-cancer-research.com/content/8/1/R12
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tive projects to use data from each cohort. A major strength of
kConFab over the BCFR is the large number of available blood
samples per family, which allows for more accurate pene-
trance estimates, and a larger number of available samples
from known mutation carriers. The BCLC families are large,
but epidemiological data have not been systematically col-
lected, nor is there a central repository of biological specimens
for which researchers can apply.
The Tyrer-Cuzick algorithm was applied to the cohort to test its
ability to predict future breast cancer and positive BRCA1 or
BRCA2 mutation tests, with considerable success. In BRCA1
or BRCA2 mutation positive families, the highest risk quintile
included almost all the women that developed breast cancer
over the comparatively short period of four years of follow-up.
It should be noted that in these families there was already con-
siderable information on the presence of these mutations
throughout the families, and that this clearly contributed to the
high predictive power of the risk estimates. When there was
no BRCA1/2 mutation known in the family, the algorithm strat-
ified the women much less strongly. This could be interpreted
to mean that in these mutation negative families individual non-
genetic risk factors such as parity and menarche still contrib-
ute to risk in the context of a strong family history but rather
more weakly, even in aggregate, than as yet undetected major
genetic effects.
The future data and specimen accrual goals of kConFab
include recruitment of an additional 400 families to reach our
target of at least 1,200 multiple-case families, collection of
annual serum and plasma samples from a subset of women at
risk, more intensive mutation analysis of non-BRCA1/2 fami-
lies, further pathology review, and the generation of tissue
Figure 2
Relationship between estimated probability and predicted relative fre- quency or BRCA1 and BRCA2 mutations Relationship between estimated probability and predicted relative fre-
quency or BRCA1 and BRCA2 mutations. Women unaffected at time 
of interview were ranked in quintiles according to their probability of 
carrying either a (a) BRCA1 or (b) BRCA2 mutation, as estimated by a 
batch program implementing the Tyrer-Cuzick algorithm, without input 
of family or individual mutation status. The proportion of women that 
tested positive for either a BRCA1 (open bars) or BRCA2 (closed 
bars) mutation is plotted on the vertical axis.
Figure 1
Relationship between estimated cumulative probability and actual rela- tive frequency of breast cancer since ascertainment Relationship between estimated cumulative probability and actual rela-
tive frequency of breast cancer since ascertainment. Women unaf-
fected at time of interview were ranked in quintiles according to their 
cumulative risk of breast cancer since interview, calculated from the 
absolute risk estimated by a batch program implementing the Tyrer-
Cuzick algorithm. The proportion of women in each risk quintile (hori-
zontal axis: 1 lowest to 5 highest) developing breast cancer during a 
median 4.2 years follow-up is plotted on the vertical axis plus standard 
error. (a) All families; (b) BRCA1 or BRCA2 mutation positive families; 
(c) BRCA1 or BRCA2 mutation negative families.Breast Cancer Research    Vol 8 No 1    Mann et al.
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microarrays from tumors with known and unknown mutations.
These will support increasingly intensive efforts by the interna-
tional breast cancer research community to solve fundamental
questions about the causation of this disease.
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